Nieuwsfeed
- Prof. dr. Cornelis Boersma en Farminform starten partnerschap voor gepast geneesmiddelengebruik
- Miljarden extra voor onderwijs gaan o.m. naar verbetering valorisatie
- Drugs@FDA Data Files
- Biological Product Deviation Reports Annual Summaries
- Empowering Sites to Optimize Clinical Trial Performance
- FDA Roundup: June 28, 2022
- Italian Garante bans use of Google Analytics
- Some pharma companies promise to cover abortion-related travel costs — while others won't go that far yet
- Aurobindo Pharma receives warning letter from India's SEC following more FDA question marks
- Axsome's long delayed depression drug is back up for label discussions at the FDA, triggering a big spike in the share price
- Basilea tosses an oncology drug back to Merck, doubling down on antibiotics in revamp
- Charles River Laboratories to start cell and gene therapy manufacturing at UK site in September
- Europe to buy 110k doses of Bavarian Nordic's monkeypox vaccine — as EU-licensed vaccine not easily accessible
- FDA Infant Formula Update: June 28, 2022
- CVS resumes coverage of blockbuster blood thinner after price drop follows January exclusion
- #CannesLions2022: Consumer health execs call on agencies to involve patients in creative process
- #CannesLions2022 MarketingRx roundup: Pharma and health finalists packed in back of Palais basement displays; Ryan Reynolds advises humor, speed and diversity
- Breaking: Novartis details plans to ax 8,000 staffers as Narasimhan begins second phase of a global reorg
- A disappointing June for Alzheimer’s disease, with setbacks for several products
- Towards a Global Implementation of eConsent in Clinical Trials
- Ceruvia’s Phase II obsessive-compulsive disorder trial receives FDA clearance
- Kiora gets approval to begin Phase Ib retinitis pigmentosa trial
- Zonder patiënt geen rendement
- Graybug seeks alternative options for eye drugs; RA-backed epilepsy outfit secures $40M Series C
- Jazz reports surprise PhIII flop for cannabinoid drug from $7.2B GW buyout
- #CannesLions2022: Pharma and health marketers lose spotlight at creativity ad fest, but does it matter?
- Betere detectie en diagnose dankzij inzet van technologische innovatie
- #CannesLions2022: Diversity, equity and inclusion takes center stage as pharma industry is called to action
- Good laboratory practice (GLP) for safety tests on chemicals
- Linking Healthcare and Clinical Trials with Sensors
- UNICEF Innocenti | Research News | June 2022
- Spero’s UTI candidate gets the CRL hammer as the company falls into penny stock status
- A decade after its first approval, FDA expands weight loss pill's label for use in adolescents
- Re-Gen Active Lab, Inc. - 620763 - 05/27/2022
- Four months after CRL due to contaminant worries, Gilead returns to FDA for next-gen HIV drug
- Years after linking arms with Bristol Myers and both Mercks, Sutro finds its latest partner in Tokyo
- Scoop: Roche scraps one of two schizophrenia PhII trials due to missed primary endpoint
- Pharma group bets up to $1B-plus on the PhIII resurrection of a once dead-and-buried LDL drug
- EMA: Another Update of the "IRIS" Documents
- New Pharmeuropa Bio & Scientific Notes Article on Weighing according to the European Pharmacopoeia
- MHRA (UK) now also a full ICH Member
- Council Conclusions on the Development of Sustainable Public Procurement
- Kezar reports positive Phase II data of zetomipzomib for lupus nephritis
- LERU’s input to the new European Innovation Agenda
- Common Pitfalls in Preparing an IND Application
- Innovating the Science of Science: A report of the ICSSI meeting
- The Lancet more than doubles its impact factor, eclipsing NEJM for the first time ever
- BfArM Adjusts Specification for Medical Cannabis
- Cybersecurity hiring levels in clinical trial operations rose in May 2022
- Medidata introduces new technologies for trial management
Op de hoogte blijven van actueel nieuws, bijeenkomsten en publieke consultaties